Thank you to Gailp607 for sharing their experience following a bronchoscopy at the Royal Infirmary of Edinburgh💙
🗣️Tell us your story on Care Opinion here: https://t.co/meQn6GTls8
Scotlands first Fluoro Nav case today at Royal Infirmary of Edinburgh. 200 ENB in, advanced fluoroscopy should help improve yield for more challenging lesions. Great collab between Resp Med, Thoracics, Anaesthetics, Pathology and Radiology. @204Rie@gourab06@frfrom @caamesoscot
On 27th July I'm attempting to cycle 250 miles across Scotland from Stranraer to Eyemouth in one day and, in the process, raise money for the fantastic charity @Roy_Castle_Lung . If you'd like to sponsor me that would be lovely. Thanks very much https://t.co/imQ3B0gKd4
📢 SEISMIC trial published in @LancetRespirMed
Prospective singe arm interntl study of staging EBUS in patients with locally advanced NSCLC before chemoRT
PET and EBUS discordant in 37%. PET occult mets in 12% which changed treatment plan #LCSM
https://t.co/DcYdfvElpE
🚨🚨PhD position available 🚨🚨
If you are interested in tumour microenvironment research in lung cancer, then please have a look at our PhD position (with @gray_mohini) at @EdinUni_IRR and @EdinUni_CIR.
https://t.co/VdnDlLUN5W
Important document on the implementation of lung cancer screening across the the devolved nations. Led by @ChestConsultant@DRBLUNGS@emmalodowd and Philip Crosbie.
Defining the road map to a UK national lung cancer screening programme https://t.co/1lsorUZbnE
Very happy to see our paper published @CellReports
Toll-like receptor 2 orchestrates a tumor suppressor response in non-small cell lung cancer
https://t.co/Rng5hjnUKu
Check out our latest manuscript. Great team effort with @WilkoLabLife @lungsforliving@adampennycuick@boulter_lab@jucaacoco amongst others!
Toll-like receptor 2 orchestrates a potent anti-tumor response in non-small cell lung cancer https://t.co/8x0hoTG5EI